Lonza Group AG / Key word (s): Annual Results/Sustainability Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual and Sustainability Reports 03-Apr-2025 / 07:00 CET/CEST ...

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...

These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal ...

Carisma Therapeutics Inc, a Philadelphia biotech company founded by two University of Pennsylvania researchers, has slashed ...

Our valuation report unveils the possibility Moderna's shares may be trading at ... Despite its revenue forecast of 17.6% annual growth, challenges remain as the company is forecast to remain ...

CureVac N.V. secured funding with GSK amid financial struggles, while a key patent win boosts stock. Click for why my ...

CAMBRIDGE, MA / ACCESS Newswire / February 25, 2025 / Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 45th Annual Health ...

Fintel reports that on March 13 ... of companies with the largest price target upside. The projected annual revenue for Moderna is 8,019MM, an increase of 147.81%. The projected annual non ...